- Trials with a EudraCT protocol (47)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
47 result(s) found for: cannabidiol.
Displaying page 1 of 3.
EudraCT Number: 2019-003591-40 | Sponsor Protocol Number: 131082019 | Start Date*: 2020-06-16 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie | ||
Full Title: Efficacy of Cannabidiol in Treatment of Pain due to symptomatic Osteoarthritis of the Knee: A randomized, double-blind, placebo-controlled | ||
Medical condition: Painful osteoarthritis of the knee | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005198-38 | Sponsor Protocol Number: CANNA1 | Start Date*: 2018-10-26 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Tetra-hydro-cannabinol, cannabidiol and their combination for the treatment of peripheral neuropathic pain. A randomised placebo-controlled trial. | |||||||||||||
Medical condition: Peripheral neuropathic pain due to polyneuropathy, postherpetic neuralgia, or peripheral nerve injury (surgical or traumatic). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003529-41 | Sponsor Protocol Number: ABR58805 | Start Date*: 2017-02-22 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia | ||
Medical condition: Schizophrenia patients | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002315-98 | Sponsor Protocol Number: MedicalcannabisMSSCI2018 | Start Date*: 2018-12-06 | ||||||||||||||||
Sponsor Name:Aarhus Universitetshospital | ||||||||||||||||||
Full Title: The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial | ||||||||||||||||||
Medical condition: Central neuropathic pain and spasticity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002819-21 | Sponsor Protocol Number: GWND19189 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: An exploratory, Phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002942-33 | Sponsor Protocol Number: GWEP1428 | Start Date*: 2015-10-27 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P) | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002786-35 | Sponsor Protocol Number: CUA1 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:Charlotte Uggerhøj Andersen | |||||||||||||
Full Title: Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis. | |||||||||||||
Medical condition: Chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002939-34 | Sponsor Protocol Number: GWEP1424 | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome. | |||||||||||||
Medical condition: Dravet syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017080-41 | Sponsor Protocol Number: GWMD09112 | Start Date*: 2010-04-19 | |||||||||||
Sponsor Name:GW Pharma Ltd. | |||||||||||||
Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease. | |||||||||||||
Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003271-18 | Sponsor Protocol Number: GWSP20105 | Start Date*: 2021-06-07 | ||||||||||||||||
Sponsor Name:GW Pharma Limited | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis | ||||||||||||||||||
Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Ongoing) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004904-50 | Sponsor Protocol Number: GWEP15100 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study. | |||||||||||||
Medical condition: Infantile Spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002625-29 | Sponsor Protocol Number: GWSP19066 | Start Date*: 2020-01-14 | ||||||||||||||||
Sponsor Name:GW Pharma Limited | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis | ||||||||||||||||||
Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000995-24 | Sponsor Protocol Number: GWEP1332 | Start Date*: 2014-09-09 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young ... | |||||||||||||
Medical condition: Dravet Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000936-17 | Sponsor Protocol Number: GWEP1560 | Start Date*: 2019-07-23 | ||||||||||||||||
Sponsor Name:GW Research Ltd | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of GWP42003-P in Conjunction with Hypothermia in Neonates with ... | ||||||||||||||||||
Medical condition: Neonatal Hypoxic-Ischemic Encephalopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001382-32 | Sponsor Protocol Number: BCT-521-201 | Start Date*: 2019-11-26 | |||||||||||
Sponsor Name:Beckley Canopy Therapeutics Ltd. | |||||||||||||
Full Title: A Double-Blind, Randomized Phase 1/2 Study to Assess the Efficacy and Safety of BCT-521 Versus Placebo for Pain Associated With Cancer in Patients Already Receiving Standard of Care Treatment With ... | |||||||||||||
Medical condition: Pain associated with cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003574-13 | Sponsor Protocol Number: 020683 | Start Date*: 2018-03-08 | ||||||||||||||||
Sponsor Name:Aalborg university hospital dept. of rheumatology | ||||||||||||||||||
Full Title: The NordCAN study: Cannabis treatment in hand osteoarthritis and psoriatic arthritis. A randomized, double-blind placebo controlled study | ||||||||||||||||||
Medical condition: Psoriatic Arthritis Hand Osteoarthritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002154-12 | Sponsor Protocol Number: GWEP1521 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:GW Research Ltd. | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experi... | |||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001834-27 | Sponsor Protocol Number: GWEP1415 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes | |||||||||||||
Medical condition: Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) PL (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002138-13 | Sponsor Protocol Number: GWSP0702 | Start Date*: 2007-09-13 |
Sponsor Name:GW Pharma Ltd. | ||
Full Title: A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). | ||
Medical condition: Symptoms of spasticity in multiple sclerosis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002531-32 | Sponsor Protocol Number: GWCL0405 | Start Date*: 2005-07-28 |
Sponsor Name:GW Pharma Ltd | ||
Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia | ||
Medical condition: Peripheral neuropathic pain associated with allodynia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.